Form 4: Corcept Therapeutics Director David Mahoney Granted 15,000 Stock Options
Insider Transaction Report
Corcept Therapeutics Inc. director David L. Mahoney was granted 15,000 stock options with an exercise price of $72.27, vesting monthly over one year.
Summary
- David L. Mahoney, a Director of Corcept Therapeutics Inc. (CORT), was granted 15,000 stock options.
- The stock options have an exercise price of $72.27 per share.
- These options will vest ratably in equal monthly installments over a one-year period, commencing on June 10, 2025.
- The vesting of the options is contingent upon Mr. Mahoney's continued service on each monthly vesting date.
- The granted options are set to expire on June 10, 2035.
Sentiment
Score: 7
Explanation: The grant of stock options to a director is a routine compensation event, generally viewed as neutral to slightly positive as it aligns the director's interests with shareholder value creation, without indicating any immediate operational or financial changes.
Positives
- The grant of 15,000 stock options to Director David L. Mahoney aligns his interests with those of shareholders, incentivizing long-term performance and value creation for Corcept Therapeutics.
Future Outlook
The document indicates that the granted stock options will vest monthly over a one-year period, subject to the director's continued service, aligning future incentives with company performance.
Industry Context
This Form 4 filing represents a routine insider transaction, specifically an equity grant to a director, which is a common practice in the biotechnology and pharmaceutical industry to align management and board interests with shareholder value.
Stakeholder Impact
- Shareholders: The equity grant to a director is intended to align the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.
Next Steps
- Monthly vesting of the 15,000 stock options over a one-year period, contingent on David L. Mahoney's continued service as a director.
Key Dates
| Date | Description |
|---|---|
| 06/10/2025 | Date of earliest transaction (grant date of stock options) and start of the one-year vesting period. |
| 06/12/2025 | Date the Form 4 was signed by the attorney-in-fact for David Mahoney. |
| 06/10/2035 | Expiration date of the granted stock options. |
Keywords
SEC Form 4, Insider Transaction, Stock Options, Director Compensation, Equity Grant, Corcept Therapeutics, CORT
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.